Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for moderate COVID-19
IRCT20210517051326N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of pentoxifylline in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Reduction in respiratory distress symptoms and Improvement in oxygen saturation. Started May 2022; status: completed.
02
Drugs
pentoxifylline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210517051326N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210517051326N1.